



krebsforschung schweiz
recherche suisse contre le cancer
ricerca svizzera contro il cancro
swiss cancer research

CSSS: Conference on State of Science in Sarcoma 2022

Agenda May 20th & 21st 2022

Friday May 20 th 2022 – Agenda Day 1		
INPUT TALKS Diagnostic Disciplines		
01:00pm	What raises the suspicion of STS	Thomas Brodowicz
01:05pm	Radiology - 2022 where do we stand	Wolfgang Kunz (virtually)
01:25pm	Pathology - 2022 where do we stand	Eva Wardelmann
01:45pm	How to integrate information from Radiology & Pathology in 2022	Eva Wardelmann / Wolfgang Kunz
01:50pm	Discussion	All
02:00pm	Voting results and discussion	Joanna Szkandera / Christian Rothermundt
02:30pm	Break	
INPUT TALKS Local Therapies		
02:45pm	Surgery - 2022 where do we stand	Dimosthenis Andreou
03:05pm	Radiation Oncology - 2022 where do we stand	Rick Haas
03:25pm	Sequence	Rick Haas / Dimosthenis Andreou

03:35pm	Discussion	All
03:45pm	Voting results and discussion	Joanna Szkandera / Christian Rothermundt
04:15pm	Break	
INPUT TALKS Systemic Therapies		
04:30pm	Curative treatment - 2022 where do we stand	Jean-Yves Blay / Robin Jones
04:50pm	Discussion	All
05:00pm	Palliative treatment - 2022 where do we stand	Ian Judson
05:20pm	Discussion	All
05:30pm	Voting results and discussion	Joanna Szkandera / Christian Rothermundt
06:00pm	End of day 1	
Saturday May 21st 2022 – Agenda Day 2		
09:00am	How Radiology & Pathology can guide the Medical Oncologist	Eva Wardelmann / Bernadette Liegl- Atzwanger / Christina Messiou
09:45am	Multidisciplinary treatment concepts for RPS	Jens Jakob / Lars Lindner / Sylvie Bonvalot / Aisha Miah / Christina Messiou
10:30am	Voting for attendees	Ingrid Desar / Christian Rothermundt
11:00am	Break	
11:15am	Multidisciplinary management of oligometastatic disease	Hans Gelderblom / Rick Haas / Robin Jones / Jens Jakob / Dimosthenis Andreou
12:15pm	Politics in sarcoma	Ian Judson / Jean-Yves Blay / Thomas Cerny
01:00pm	Meeting close	

This program is supported by an Independent educational grant from
Lotte & Adolf Hotz-Sprenger Stiftung
Bayer, Bristol Myers Squibb, Deciphera, Ipsen, Novartis, PharmaMar and Roche Pharma AG